In very future, majority of the population will have access to their genetic background and they will be able to take it their doctor and will expect to receive personalized treatment rather than a drug that has worked for millions of people but not guaranteed to work for them. Pharmaceutical...
An analysis from the phase 2 CLL2-BAAG trial (NCT03787264) showed that cell-free DNA (cfDNA)–based minimal residual disease (MRD) testing was feasible in patients with chronic lymphocytic leukemia (CLL) who were treated with time-limited venetoclax (Venclexta), acalabrutinib (Calquence), an...
PI3K, and BCL2.4,5National Comprehensive Cancer Network guidelines recommend acalabrutinib (Calquence) plus or minus obinutuzumab (Gazyva), ibrutinib (Imbruvica), or venetoclax (Venclexta) plus obinutuzumab